INTRODUCTION
Promulgation of clinical practice guidelines (CPG) is intended to synthesise available medical information and improve quality of care.
Barriers to their application, however, often limit their implementation in daily practice. , Actual application depends on [3 -9 ] [10 11 ] a variety of indicators, including confidence in the guideline developer , , accessibility of the guidelines, their ease of use , and [12 13 ] [ 14 ] applicability to specific patients, as well as the strategies used to promote implementation. , [15 16 ] Rheumatoid arthritis (RA) is interesting to consider from this point of view because treatment for it has changed substantially in recent years. Key aspects of these changes include early start of treatment, use of drugs that can prevent joint destruction (that is, proven to prevent or delay structural damage) and disease flares, importance of regular monitoring of disease activity and structural changes to ensure tight control of the disease.
For this reason, several expert groups and professional societies have issued guidelines on this [17 -22 ] topic in recent years. , , , [1 2 23 24 ] Two different groups produced two sets of guidelines about prescription of first-line disease-modifying antirheumatic drugs (DMARD) in early RA: the French Society of Rheumatologists STPR working group (French acronym for Therapeutic strategies in
RA ) and a EULAR expert group (European League Against Rheumatism). The STPR guidelines present a decision tree for choosing " [2 ] the first DMARD to be used in early RA (less than 6 months duration). The EULAR guidelines put methotrexate as the anchor drug [1 ] that should be used first in patients at risk of developing persistent disease. [2 ] To compare these CPG with the usual care provided by rheumatologists, we used the data of a French nationwide cohort, ESPOIR (acronym for Study and Follow-up of Undifferentiated Early Arthritis ), which included patients between 2002 and 2005. It is " " [25 ] important to note the chronology: the ESPOIR inclusion period overlapped with the production and diffusion of both CPG. The STPR results were presented at the ACR annual scientific meeting in November 2004 and published in January 2006, while the EULAR results were presented at the EULAR annual scientific meeting in June 2005 and published in January 2007. Our aim therefore was not to assess adherence to guidelines. Instead we sought to explore the potential gap between daily rheumatologic practice and guidelines for the first DMARD prescription in early RA, before their dissemination, for such gaps are likely to be barriers to implementation.
PATIENTS AND METHODS

Study design
Our primary objective was to assess the conformity between the first DMARD prescribed to patients in the ESPOIR cohort and the DMARD recommended by each of the two sets of guidelines. At the same time we assessed the determinants of this conformity, the influence of the patient s inclusion date, and the extent of the gap with the STPR guidelines. Our secondary objective was to explore the ' reasons for any discrepancies we observed between the rheumatologists decisions and CPG. Accordingly, in cases where the treatment did ' not match the STPR guidelines, we sent a questionnaire (described in Appendices) to the patients attending rheumatologists.
'
Patients
The ESPOIR cohort ESPOIR was a nationwide prospective cohort study of adults (18 to 70 years old) sponsored by the French Society of Rheumatology.[ , Inclusion criteria were: inflammatory arthritis for at least 6 weeks but not longer than 6 months, involvement of more than two 25 26 ] joints, clinical diagnosis of RA as certain or probable or clinical diagnosis of undifferentiated arthritis potentially becoming RA, and no DMARD or steroid treatment since the onset of symptoms. Patients with other definite inflammatory rheumatic diseases or with too much uncertainty of developing RA were excluded.
Recruitment in 14 university hospital rheumatology departments was conducted through several media inviting patients and physicians to participate in each regional area. Each centre acted as an observational centre and did not interfere with patient treatment, except in charge of a patient. The patients were routinely treated and followed by private rheumatologists of the geographical area.
In all, 813 patients were recruited from November 2002 to April 2005 and have been longitudinally followed since then, seen every 6 months in the 14 hospital centres participating in the project. Baseline data is updated at the 6-month follow-up.
RA diagnosis
A selection of patients most at risk to be RA patients was conducted in ESPOIR database, to allow a study of conformity with guidelines in case of the less diagnostic uncertainty of RA. Therefore fulfilment of ACR criteria and the attending rheumatologist s [27 ] ' diagnostic certainty at baseline (0 to 100 visual analogue scale VAS) were used.
-'Definite RA was defined if patients met at least 4 (of 7) ACR criteria and diagnostic certainty was rated at 75 (threshold determined ' ≥ by ESPOIR steering committee). Probable RA was defined as meeting at least 3 ACR criteria, even with a diagnostic certainty <75.
' '
Guidelines
STPR guidelines:[1 ]
The STPR decision tree determines the DMARD to prescribe according to 3 items: level of disease activity based on the Disease EULAR guidelines: [2 ] These guidelines recommend methotrexate as a first treatment for early arthritis at risk to be persistent, since it acts on structural damage, prevents flares and may thus be viewed as an anchor drug for additional DMARDs in case of inadequate response.
Conformity with guidelines
We then assessed conformity with the STPR and the EULAR guidelines. To evaluate STPR conformity we needed data about the 3 items of the STPR algorithm whereas to evaluate EULAR conformity we were able to compare therapeutic decision with the recommended treatment everytime.
Possible determinants of conformity studied were: social and demographic patient characteristics (sex, age, ethnic origin, educational level, comorbidities), disease characteristics (number of tender joints, number of swollen joints, symptoms duration, DAS28 score, HAQ score), prognostic factors (presence of rheumatoid factor (RF) or Anti-CCP antibodies (CCP-Abs), presence of radiographic erosions, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels), category of diagnostic certainty (definite versus probable RA) and finally the geographical area of inclusion.
In view of the length of the ESPOIR inclusion period, we also assessed the influence of the inclusion period, subdivided into four When treatment was not the same as the STPR guidelines, the discrepancy could be either important or slight. We therefore pooled the different treatment decisions in 3 broad categories: no DMARD prescription, prescription of DMARD that only prevents flares (hydroxychloroquine, gold salts, tiopronin), and prescription of at least one DMARD that prevents flares and has been proven to inhibit structural damage (methotrexate, leflunomide, sulfasalazine and TNF-blocker agents). We then assessed the observed and expected (according to STPR guidelines) DMARD prescriptions according to these three categories.
Mail survey
In May 2007, a survey was mailed to the initial attending rheumatologists of all patients whose treatment differed from STPR guidelines. The questionnaire was carefully phrased to not seem judgmental, especially since no aspect of either CPG was mandatory. All therapeutic options were presented at the same level, without any labeling as good or bad, optimal or suboptimal. The questionnaire asked about the reasons for the decision and then about awareness of the STPR and EULAR guidelines. Rheumatologists were also asked about their perception of the guidelines pertinence and the decision they would make for a similar patient visiting in 2007.
'
Statistical analysis
Statistical analysis used SAS software, version 9-1 (SAS Institute Inc., Cary, NC, USA). 
Ethics Committee
The ESPOIR study was approved by the central ethics committee of Montpellier, and written informed consent was obtained from each participant in the cohort. Both the scientific and steering committee of the ESPOIR cohort approved this study.
RESULTS
Of the 813 cohort members, 627 had definite or probable RA and were included in the further analysis. ( ) Figure 1 Baseline patient characteristics summarises the main baseline characteristics of the 627 patients. They were predominantly female (76.6 ), and their mean 
(from onset of the first persistently swollen joint) less than 15 weeks. 4 15 In all, 505 patients (80.5 of 627 patients) began DMARD treatment within a mean of 17.6 / 9.1 weeks (median 16.4 ) from the % + − onset of the first persistently swollen joint. The DMARD prescribed most frequently was methotrexate in 340 patients (54.2 of 627).
-% Combination therapies were noted in 41 patients (6.5 ). ( ) % Table 2 Conformity with guidelines Conformity with the STPR guidelines could be determined for 581 patients (92.7 ) ( ) and ranged between centres from 35 to % Figure 1 79 . Overall, 337 DMARD prescriptions (58.0 ) matched the STPR guidelines (66 in the group definite RA and 47 in the group
probable RA ).
"
Conformity with the EULAR guidelines could be determined for all 627 patients and ranged between centres from 22 to 75. 4 . In all, % 340 DMARD choices (54.2 ) matched the EULAR guidelines (61 in the group definite RA and 45 in the group probable RA ).
Analysis of determinants associated with conformity
STPR guidelines
Results of the univariate analysis are presented in . The final multivariate analysis adjusted for inclusion centre, found three Table 3 variables to be significantly associated with conformity: presence of RF or CCP-Abs and a definite diagnosis of RA were associated with ' ' better conformity (odds ratios >1), while poorer conformity was found for women patients (odds ratios <1). ( ) Table 4 EULAR guidelines
The data from the univariate analysis are not shown. The multivariate analysis, adjusted for inclusion centre, found the following significant determinants associated with better conformity: moderate and high DAS28 scores, radiographic bone erosions, and the presence of RF or CCP-Abs (odds ratios >1). ( ) Table 4 Influence of inclusion period
We observed a trend towards better conformity with the STPR guidelines over time during the ESPOIR inclusion period. We then focused on the 244 patients treated differently than the STPR guidelines recommend ( ): 116 (47.5 ) had mild to Table 5 % moderate disease (no structural damage and low or moderate DAS28 scores). In this group, 62 patients (25.4 ) had no DMARD 
DISCUSSION
Our study demonstrates a rather substantial discrepancy between the recently published guidelines for the first-line DMARD to be prescribed for patients with early RA, and daily French practice between 2002 and 2005.
We have not found similar data in the literature with which we can compare our results. Although some studies that retrospectively assessed the application of CPG for therapeutic decisions report conformity rates ranging from 40 to 60 , study designs and methods vary % greatly. , For example, in the field of rheumatology, Denoeud et al. showed that the French general practitioners treating [8 28 -30 ] osteoarthritis of the knee conform with the EULAR guidelines in 54 of the cases.
The conformity rates in our study, even before % [28 ] implementation of the CPG, are rather encouraging and suggest rheumatologists will find them acceptable.
The conformity with guidelines improved during the study period with a rate of 67 for the STPR guidelines during the last period of % ESPOIR inclusions. There were connections between the members of the STPR group and the ESPOIR steering committee as a few people participated in both groups (AC, BC, BF, RMF, XLL, OM, AS). This could have led to better dissemination of STPR guidelines in the ESPOIR inclusion centres, even if patients were followed by their usual rheumatologist. Moreover some discrepancies have been observed in the different centres which might be due to local prescription habits or impact of local opinion leaders. Some of the ESPOIR centres are also important recruitment centres for clinical trials which lead to DMARD prescriptions different from guidelines. However, treatment decisions were made by usual practising rheumatologist and not directly by the people involved in the recruitment and follow-ups of the ESPOIR patients.
Our study found quite similar rates of conformity for both sets of guidelines, which recommend methotrexate as the principal treatment in early RA. We also wondered if the results of conformity with EULAR guidelines would be different by assuming that using leflunomide as a first DMARD was equivalent to use methotrexate. The rate of conformity was then 59.2 instead of 54.2 .
% %
A key point in the recent therapeutic advances in the management of RA is the need to start treatment early with a DMARD that reduces joint damage (radiographic progression). , , Delaying its initiation in patients with early RA is thus very clearly [18 20 22 ] suboptimal treatment. The STPR and EULAR guidelines differ in that STPR grades the prescription according to disease activity and factors predictive of severity (structural damage, RF status). In particular, the STPR group does not recommend methotrexate for RA patients who have a low DAS28 and no structural damage and are negative for RF, that is, for mild or perhaps doubtful RA. The randomized controlled PROMPT study points in the same direction. It showed in a subgroup of patients with early arthritis who were negative for RF and CCP-Abs and thus might not develop RA that methotrexate did not improve patient outcomes at 3 years. The STPR guidelines rely on this concept and introduce treatment that is graded according to the potential benefit/risk ratio of methotrexate, compared with other conventional DMARDs, such as hydroxychloroquine.
It was also interesting to determine whether the patients treated differently than the STPR guidelines recommend had received a DMARD that stops joint damage. Although only 23 of the 116 patients with mild or moderate disease (20 ) , had been treated with such a % drug, negative consequences to this lack of treatment were least likely in this group. On the other hand, 60 of the 128 patients with [37 ] severe disease (47 ) had still not received a DMARD effective against structural involvement 6 months after inclusion in the study, and % their treatment can be considered suboptimal, as several authors have shown. , , [20 38 39 ] An important reason for non-conformity with guidelines and, by extension, for suboptimal care is diagnostic uncertainty, which is a well-known difficulty in the management of early RA. Classification criteria and clinical standards for diagnosis are useful after 1 or 2 years of disease, but not necessarily at the first consultation. In practice, early arthritis is frequently undifferentiated.
An RA diagnosis [40 ] is thus generally based upon the rheumatologist s opinion, perhaps after consideration of the ACR classification criteria , as here. These ' [27 ] criteria do not, however, perform as well in early arthritis as they do in established RA.
Other criteria, such as those from the Leiden
clinic , have been developed to address early RA diagnosis more specifically.
[42 ]
Some limitations in our study must be noted. Although the cohort was observational and intended for the study of routine practice, it is not certain that mere participation did not influence rheumatologists treatment decisions and thereby introduce possible bias. Furthermore, ' compliance bias undoubtedly plays a role in physicians answers to questions about their practices, because it is well known that the even ' experts answers about their prescription habits are sometimes rather far from their real practice, as Headrick et al showed.
To conclude, we found a gap between recent guidelines for treatment of early RA and daily practice by specialists during the period the guidelines were under development. In some cases, especially when the RA diagnosis is uncertain or predictive factors of severity are absent, these differences are unlikely to be harmful. In other cases, however, care appeared to be suboptimal. Future efforts will concern the establishment of reliable criteria for diagnosis of early RA, necessary to improve the implementation of the treatment guidelines.
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